Clinical trial
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced…
NCT00190671 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00190671 |
|---|---|
| Title | A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients |
| Official title | A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed, cyclophosphamide |
| Enrollment | 103 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 20, 2009 |
| Countries | Austria, Czechia, Hungary, Poland, Romania, Russia |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: